TRANSPLANTATION OF MONOCLONAL ANTIBODY‐PURGED AUTOLOGOUS BONE MARROW FOR TREATMENT OF POOR RISK COMMON ACUTE LYMPHOBLASTIC LEUKEMIA

Publisher Website
Google Scholar
Abstract
Two murine monoclonal antibodies, FMC‐8 and WM‐21, reactive with the human leucocyte differentiation antigens CD‐9 (p‐24) and CD‐10 (CALLA), respectively, have been used for purging leukemic cells from remission bone marrow. Nine patients with the common variant of acute lymphoblastic leukemia (c‐ALL) in second or subsequent remission underwent bone marrow harvesting. Bone marrow mononuclear cells underwent lytic incubation in vitro with antibodies FMC‐8 and WM‐21, and rabbit serum as a source of complement, and were then cryopreserved. A mean of 0.90 ± 0.50 times 108 nucleated cells per kilogram of recipient body weight remained after treatment, with 0.38 ± 0.24 times 108 nucleated cells and 8.3 ± 10.3 times 104 CFUGM per kg being recovered on thawing. Seven patients subsequently received marrow‐ablative treatment with high dose cyclophospharnide (120 mg/kg) and fractionated total body irradiation (12 Gy), followed by infusion of antibody‐purged autologous bone marrow. Three deaths due to sepsis occurred within the first 35 days, compounded in one patient by poor marrow engraftment. All other patients engrafted promptly, and four remain in continuous complete remission at 2, 6, 9, and 28 months after transplantation. The procedure carries a substantial risk of early toxicity, but offers a significant chance of prolonged unmain‐tained remission to selected patients with poor prognosis acute lymphoblastic leukemia.